Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From FoldRx Pharmaceuticals
Takeda will pair five cancer candidates with different mechanisms of action with Nektar's NKTR-214 and Merck follows up its Phase III disappointment verubecestat by licensing a preclinical Alzheimer's drug from Teijin.
With strong backing, F-Prime Capital Partners can make large, high-risk bets around the world — and keep doubling down. An interview with F-Prime Managing Partner Stephen Knight.
For larger organizations with interests in rare diseases, Bionest Partners believes it is necessary to maintain a separation from the rest of the company in order to keep the culture needed for successful product commercialization. Easier said than done.
Dimension Therapeutics, Inc., a company developing liver-directed treatments for diverse genetic disorders, has elected of Dr Georges Gemayel, former executive vice-president of Genzyme Corporation and Arlene M. Morris, former CEO of Syndax Pharmaceuticals, to its board of directors. Dimension has also announced that Donald J. Hayden, Jr. is leaving his position as a member of the board. Previously, Gemayel was executive chair of Vascular Magnetics Inc., Syndexa, and FoldRx Pharmaceuticals, Inc (acquired by Pfizer). And Morris was previously president and CEO of Affymax, Inc.